Catimor Coffee (Coffea arabica)

Catimor is a hybrid Coffea arabica cultivar derived from Timor Hybrid and Caturra, containing chlorogenic acids and approximately 1–2% caffeine by dry weight. Its primary bioactive compounds—chlorogenic acids and caffeine—interact with adenosine receptors and modulate Nrf2-mediated antioxidant pathways, though no clinical trials have specifically studied this cultivar.

Origin & History

Catimor is a hybrid coffee cultivar developed in Portugal in 1959 by crossing Caturra (C. arabica) with Híbrido de Timor, resulting in disease-resistant lines like Catimor 129, T-8667, T-5269, and T-5175. It is a compact, dwarf bush with high yield (4-5 tons per hectare) and coffee leaf rust resistance, optimally grown at 500-1650 meters altitude. The cultivar produces small, round beans with 1-2% caffeine content, lower than typical Robusta varieties.

Historical & Cultural Context

Catimor has no historical traditional medicine uses as it is a modern hybrid released since the 1980s specifically for agricultural yield and disease resistance. While coffee (C. arabica) has centuries of traditional stimulant use in Ethiopian and Yemeni cultures, Catimor postdates these practices and was developed purely for commercial cultivation purposes.

Health Benefits

• General antioxidant effects from chlorogenic acids (no Catimor-specific evidence)
• Potential adenosine receptor antagonism from caffeine content (1-2%) (no clinical trials)
• Possible anti-inflammatory activity via Nrf2 pathway activation (theoretical, no Catimor studies)
• Lower caffeine content may reduce anxiety compared to other coffee varieties (no direct evidence)
• Standard coffee benefits may apply but remain unstudied for this specific cultivar

How It Works

Caffeine in Catimor (approximately 1–2% dry weight) competitively antagonizes adenosine A1 and A2A receptors, reducing inhibitory neurotransmission and promoting alertness. Chlorogenic acids, particularly 5-caffeoylquinic acid, activate the Nrf2/Keap1 pathway, upregulating antioxidant response element (ARE)-driven genes including heme oxygenase-1 (HO-1) and glutathione S-transferase. These same chlorogenic acids also inhibit glucose-6-phosphatase activity in vitro, suggesting a possible mechanism for glycemic modulation, though this has not been confirmed in Catimor-specific research.

Scientific Research

No human clinical trials, RCTs, or meta-analyses specifically on Catimor coffee were identified in biomedical literature. While general coffee (C. arabica) studies exist on caffeine and antioxidants, none differentiate Catimor or evaluate its unique hybrid traits. The cultivar lacks specific biomedical research despite its agricultural importance.

Clinical Summary

No clinical trials have been conducted specifically on Catimor coffee or its extracts. Evidence for its bioactive compounds is extrapolated from broader Coffea arabica and green coffee bean research; for example, a 2012 meta-analysis of green coffee extract (pooling studies with 50–200 participants) found reductions in systolic blood pressure of approximately 3–4 mmHg attributable to chlorogenic acids. Caffeine's adenosine antagonism has been characterized extensively in controlled crossover trials, but Catimor's relatively lower caffeine content compared to other arabica cultivars means these effects may be attenuated. Overall, the evidence base for Catimor as a distinct supplement ingredient is absent, and all proposed benefits remain theoretical extrapolations.

Nutritional Profile

Catimor coffee beans (green, per 100g dry weight) contain approximately 10-13g protein (rich in glutamic acid, aspartic acid, and leucine), 0-1g fat in brewed form (green beans contain 10-16g lipids including linoleic acid ~40-45% of fatty acid profile and palmitic acid ~25-30%), and negligible digestible carbohydrates in brewed coffee. Key bioactive compounds include chlorogenic acids (CGAs) at 6-10g per 100g green bean dry weight — primarily 5-caffeoylquinic acid (5-CQA) — with Catimor reported toward the lower-to-mid range of arabica CGA concentrations due to robusta introgression affecting phenolic profiles. Caffeine content is approximately 1.0-1.5% of dry green bean weight (slightly lower than many arabica varieties, attributed to Timor hybrid genetics), translating to roughly 60-100mg per standard 200ml brewed cup depending on preparation. Trigonelline is present at approximately 0.6-1.0g per 100g green beans, a precursor to niacin (vitamin B3) upon roasting, generating approximately 10-30mg niacin equivalents per 100g roasted bean. Melanoidins (high-molecular-weight Maillard reaction products) form during roasting at 25-30% of roasted bean mass, contributing antioxidant and prebiotic-like activity. Minerals per 100ml brewed coffee include potassium (~80-100mg, high bioavailability), magnesium (~6-8mg), and trace manganese (~0.05mg). Cafestol and kahweol diterpenes are present in unfiltered preparations at 2-4mg per cup, absent in paper-filtered methods. Riboflavin (B2) is present at approximately 0.1mg per 100ml brewed. Bioavailability note: CGAs exhibit 30-60% absorption in the small intestine with remainder metabolized by colonic microbiota into phenylpropionic and hydroxycinnamic acid derivatives; caffeine is nearly 100% bioavailable orally. Catimor-specific compositional data remains limited, with most values extrapolated from arabica/robusta hybrid studies and regional agronomic reports from Southeast Asia and Latin America.

Preparation & Dosage

No clinically studied dosage ranges exist for Catimor coffee. General coffee consumption guidelines suggest 3-5 cups daily (≈300-500 mg caffeine), but Catimor's lower caffeine content (1-2%) would require adjusted intake for equivalent effects. No standardized extracts or powder formulations have been studied. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

L-theanine, MCT oil, milk/cream, cacao, cinnamon

Safety & Interactions

Caffeine content in Catimor, while lower than many arabica varieties, can still cause insomnia, tachycardia, anxiety, and elevated blood pressure at higher intake levels, particularly in caffeine-sensitive individuals. Chlorogenic acids may potentiate the hypoglycemic effects of metformin or insulin, warranting caution in diabetic patients. Caffeine interacts with adenosine-based medications, MAO inhibitors, and anticoagulants such as warfarin by competing for hepatic CYP1A2 metabolism, potentially altering drug plasma levels. Pregnant individuals are generally advised to limit total caffeine intake to under 200 mg per day; Catimor's lower caffeine profile may offer a marginal advantage, but concentrated extracts should still be used cautiously.